MedDiet Adherence Seems Beneficial for Benign Prostatic Hyperplasia
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 14, 2025 -- In patients with benign prostatic hyperplasia (BPH), adherence to the Mediterranean diet (MedDiet) is associated with improved urinary function and reduced lower urinary tract symptoms (LUTS), according to a study published online July 6 in The Prostate.
İsa Dağlı, from the University of Health Sciences in Ankara, Turkey, and colleagues examined the impact of adherence to the MedDiet on uroflowmetry parameters and International Prostate Symptom Scores (IPSS) in patients presenting with LUTS in a prospective study involving 400 patients. The patients were divided into two groups: MedDiet-adherent (AMD) and nonadherent (NAMD; 193 and 207 patients, respectively). The Mediterranean Diet Adherence Screener (MEDAS) was used to assess adherence.
The researchers found that compared with patients in the NAMD group, patients in the AMD group exhibited a significantly higher maximum urinary flow rate (Qmax; 13.87 ± 0.21 versus 12.08 ± 0.19) and lower IPSS (median, 9 versus 17). There were no differences between the groups in average urinary flow rate, postvoid residual urine volumes, or body mass index. There were positive correlations between MEDAS scores and Qmax, while a strong negative correlation was seen between IPSS and MEDAS scores.
"Due to the observational nature of the study, these associations should be interpreted with caution. The MedDiet might offer a promising, noninvasive approach to managing BPH," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes
THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.